The Cost-Effectiveness of Early Access to HIV Services and Starting cART in the UK 1996–2008
Open Access
- 14 December 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12), e27830
- https://doi.org/10.1371/journal.pone.0027830
Abstract
To calculate use, cost and cost-effectiveness of people living with HIV (PLHIV) starting routine treatment and care before starting combination antiretroviral therapy (cART) and PLHIV starting first-line 2NRTIs+NNRTI or 2NRTIs+PIboosted, comparing PLHIV with CD4≤200 cells/mm3 and CD4>200 cells/mm3. Few studies have calculated the use, cost and cost-effectiveness of routine treatment and care before starting cART and starting cART above and below CD4 200 cells/mm3. Use, costs and cost-effectiveness were calculated for PLHIV in routine pre-cART and starting first-line cART, comparing CD4≤200 cells/mm3 with CD4>200 cells/mm3 (2008 UK prices). cART naïve patients CD4≤200 cells/mm3 had an annual cost of £6,407 (95%CI £6,382 to £6,425) PPY compared with £2,758 (95%CI £2,752 to £2,761) PPY for those with CD4>200 cells/mm3; cost per life year gained of pre-cART treatment and care for those with CD4>200 cells/mm3 was £1,776 (cost-saving to £2,752). Annual cost for starting 2NRTIs+NNRTI or 2NRTIs+PIboosted with CD4≤200 cells/mm3 was £12,812 (95%CI £12,685–£12,937) compared with £10,478 (95%CI £10,376–£10,581) for PLHIV with CD4>200 cells/mm3. Cost per additional life-year gained on first-line therapy for those with CD4>200 cells/mm3 was £4639 (£3,967 to £2,960). PLHIV starting to use HIV services before CD4≤200 cells/mm3 is cost-effective and enables them to be monitored so they start cART with a CD4>200 cells/mm3, which results in better outcomes and is cost-effective. However, 25% of PLHIV accessing services continue to present with CD4≤200 cells/mm3. This highlights the need to investigate the cost-effectiveness of testing and early treatment programs for key populations in the UK.Keywords
This publication has 16 references indexed in Scilit:
- Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006PLOS ONE, 2011
- Combination prevention: a deeper understanding of effective HIV preventionAIDS, 2010
- Late diagnosis of HIV in Europe: definitional and public health challengesAIDS Care, 2009
- British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008HIV Medicine, 2008
- The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004)AIDS, 2006
- Cost-Effectiveness of Highly Active Antiretroviral Therapy in South AfricaPLoS Medicine, 2005
- Need for differential discounting of costs and health effects in cost effectiveness analysesBMJ, 2005
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004
- Naively changing HAARTHIV Medicine, 2002
- Analysis of Incomplete Multivariate Data (Monographs on Statistics and Applied Probability, No. 72)Journal of the American Statistical Association, 2000